Earnings Summary

Ironwood Pharmaceuticals, Inc.’s revenue jumped 7.72% since last year same period to $94.21Mn in the Q4 2017. On a quarterly growth basis, Ironwood Pharmaceuticals, Inc. has generated 8.5% jump in its revenue since last 3-months.

Ironwood Pharmaceuticals, Inc.’s net profit jumped 189.49% since last year same period to $12.09Mn in the Q4 2017. On a quarterly growth basis, Ironwood Pharmaceuticals, Inc. has generated 137.42% jump in its net profits since last 3-months.

Ironwood Pharmaceuticals, Inc.’s net profit margin jumped 183.07% since last year same period to 12.83% in the Q4 2017. On a quarterly growth basis, Ironwood Pharmaceuticals, Inc. has generated 134.49% jump in its net profit margins since last 3-months.

Ironwood Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.3 - a 11.11% jump from last quarter’s estimates.

Ironwood Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 0.3.

Ironwood Pharmaceuticals, Inc.’s earning per share (EPS) fell -15.15% since last year same period to 0.28 in the Q3 2022. This indicates that the Ironwood Pharmaceuticals, Inc. has generated -15.15% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ironwood Pharmaceuticals, Inc.’s return on assets (ROA) stands at 0.14.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ironwood Pharmaceuticals, Inc.’s return on equity (ROE) stands at 0.29.